



BIBLIOGRAFIA SIOOT

Aggiornamento al 28 agosto 2026

PUBBLICATI

1. Franzini M, Chirumbolo S, Ricevuti G, Valdenassi L. SIOOT® Adjunct Oxygen-Ozone Therapy Against Multidrug-Resistant Bacteria: A Pilot Study of 257 Cases. *Antibiotics* (Basel). 2026 Aug 10;15(8):768. **PUNTEGGIO CITE SCORE 10.1 primo quartile 95%**
2. Chirumbolo S, Valdenassi L, Pandolfi S, Vaiano F, Ricevuti G, Tirelli U, Simonetti V, Franzini M. Protocols in the therapeutic use of medical ozone: a matter of debate. *Med Gas Res*. 2026 Dec 1;16(4):557. **PUNTEGGIO CITE SCORE 4.8 primo quartile 75%**
3. Langella A, Franzini M, Valdenassi L, Vaiano F, Tirelli U, Chirumbolo S. Immunological Considerations and Biological Consequences of Intradiscal Needle Procedures: Implications for Chemo-Nucleolysis and Oxygen-Ozone Therapy. *Maedica* (Bucur). 2026 Jun;21(2):464-467.
4. Valdenassi L, Chirumbolo S, Corsetti MT, Bugiani O, Franzini M, Marcello A, Bellardi D, Tirelli U, Rossi E. Oxygen-ozone action on Isaac's syndrome: a case report. *Eur Rev Med Pharmacol Sci*. 2026 Jun;30(6):195-201.
5. Franzini M, Valdenassi L, Chirumbolo S. Follow up of a previous aspergillosis case report treated with oxygen-ozone therapy, reporting clinical remission of the lung fungal infection. *Int Immunopharmacol*. 2026 May 12;182:116831. **PUNTEGGIO CITE SCORE 8.4 primo quartile 88%**
6. Franzini M, Valdenassi L, Chirumbolo S. The Translational Medicine Regarding Ozone in Saline Solutions. Comment on Armeli et al. Ozone Saline Solution Polarizes Microglial Cells Towards an Anti-Inflammatory Phenotype. *Molecules* 2025, 30, 3932. *Molecules*. 2026 Apr 3;31(7):1187. **PUNTEGGIO CITE SCORE 8.6 primo quartile 87%**
7. Carella C, La Sorsa V, Macchia I, Giancristofaro S, Pagnotta M, Pietraforte D, Sanchez M, Zini M, Cairo G, Fabiani M, Monaco M, Del Grosso M, Camilli R, Errico G, Pandolfi S, Valdenassi L, Franzini M, Cenci A. Bactericidal Action and in Vitro Immunomodulatory Effects of Ozone on Methicillin-Resistant *Staphylococcus Aureus*. *Front Biosci* (Elite Ed). 2026; ?(?):?. doi: 10.31083/?
8. Franzini M, Chirumbolo S, Vaiano F, Valdenassi L, Giannetti F, Chierchia M, Tirelli U, Bonacina P, Poggi GL, Langella A, Pieracci EM, Giannetti C, Giannetti RA. How safe are oxygen-ozone therapy procedures for spine disc herniation? The SIOOT protocols for treating spine disorders. *J Imaging* 2025; 11(12), 428 **PUNTEGGIO CITE SCORE 6.7 primo quartile 87%**
9. Chirumbolo S, Valdenassi L, Tirelli U, Franzini M. The unusual trend in using IV methylene blue to prevent oxidative stress and promote wellbeing. *Int Immunopharmacol*. 2025 Dec 10;167:115786. **PUNTEGGIO CITE SCORE 8.4 primo quartile 88%**
10. Bertossi D, Franzini M, Valdenassi L, Tirelli U, Chirumbolo S. Ozone in Botulinum Toxin-Induced Ptosis: Some Comments. *J Cosmet Dermatol*. 2026 Apr;25(4):e70850. **PUNTEGGIO CITE SCORE 4.9 primo quartile 80%**



11. Franzini M, Valdenassi L, Vaiano F, Tirelli U, Chirumbolo S. Critical comments on ultrasound-guided paravertebral oxygen-ozone injections. *J Back Musculoskelet Rehabil.* 2026 Mar 17;10538127261432690. **PUNTEGGIO CITE SCORE 2.7 secondo quartile 58%**
12. Franzini M, Valdenassi L, Bertossi D, Tirelli U, Chirumbolo S. Oxygen-ozone therapy in the osteonecrosis of the jaw: some comments. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2026 May;141(5):717-718. **PUNTEGGIO CITE SCORE 3.7 primo quartile 79%**
13. Franzini M, Valdenassi L, Ciatti M, Chirumbolo S. Comment on "Ozonized Hydrogel and Chlorhexidine Gel for Peri-Implant Mucositis: A 24-Month Randomized Controlled Trial". *Oral Dis.* 2026 Jan 29. **PUNTEGGIO CITE SCORE 7.3 primo quartile 97%**
14. Tirelli U, Chirumbolo S. Are new psychoactive substances driving sudden unexpected deaths and violence among youth in the European countries? *Intern Emerg Med.* 2025 Nov 3. doi: 10.1007/s11739-025-04180-2. **PUNTEGGIO CITE SCORE 6.3 primo quartile 95%**
15. Franzini M, Valdenassi L, Chirumbolo S. Joint disorders and ozone therapy: some comments. *Inflammopharmacology.* 2025 Sep 10. doi: 10.1007/s10787-025-01935-3. **PUNTEGGIO CITE SCORE 8.4 primo quartile 88%**
16. Tirelli U, Franzini M, Chirumbolo S. Wheat and chaff in Myalgic Encephalomyelitis/Chronic fatigue syndrome (ME/CFS) in clinics and laboratory. *J Transl Med.* 2026 Jan 5;24(1):20. **PUNTEGGIO CITE SCORE 8.8 primo quartile 94%**
17. Chirumbolo S, Valdenassi L, Bertossi D, Loprete F, Tirelli U, Franzini M. A conceptual model of oxygen-ozone therapy as a modulator of aging via the HMGB1 pathway. *Biogerontology.* 2025 Dec 23;27(1):28. **PUNTEGGIO CITE SCORE 7.5 primo quartile 91%**
18. Chirumbolo S, Franzini M, Tirelli U, Valdenassi L. Ozone therapy and the role of the glutathione pathway 2025 *Inflammopharmacology*, in press **PUNTEGGIO CITE SCORE 8.4 primo quartile 88%**
19. Franzini M, Chirumbolo S, Valdenassi L. Haemolysis Generated with the Use of Glass Bottles Instead of PVC, DEHP-Free Blood Collection Bags in the Oxygen-Ozone Therapy. *Maedica (Bucur).* 2025 Jun;20(2):257-263.
20. Chirumbolo S, Masiello G, Franzini M, Richelmi T, Tirelli U, Valdenassi L. The ability of ozone to counteract multidrug-resistant bacteria if used as an adjunct therapy: a bioinformatic modelling. *J Med Microbiol.* 2025 Jun;74(6):002035. **PUNTEGGIO CITE SCORE 4.3 secondo quartile 51%**
21. Chirumbolo S, Franzini M, Ricevuti G, Valdenassi L. Intravenous glutathione should not be mismatched with ozone as an antioxidant therapy. *Biomed Pharmacother.* 2025 May 22;188:118197. **PUNTEGGIO CITE SCORE 12.8 primo quartile 94%**
22. Chirumbolo S, Masiello G, Chirumbolo S, Valdenassi L, Tirelli U, Richelmi T, Franzini M. Sonic transdermal transfer of ozone and its use in oxygen-ozone therapy. Wheat and chaff. *Int Immunopharmacol.* 2025 May 13;158:114805. **PUNTEGGIO CITE SCORE 8.4 primo quartile 80%**
23. Franzini M, Valdenassi L, Vaiano F, Chirumbolo S. Adverse effects following some practices of ozone therapy for disc herniation. Critical comments. *Int J Surg Case Rep.* 2025 May 7;131:111411. **PUNTEGGIO CITE SCORE 1.1 terzo quartile 37%**
24. Masiello G, Franzini M, Richelmi T, Tirelli U, Valdenassi L, Chirumbolo S. Ozone therapy addresses neuropathic pain in ulcerous wounds. *Med Gas Res.* 2025 Sep 1;15(3):448-449. **PUNTEGGIO CITE SCORE 5.1 secondo quartile 74%**



25. Valdenassi L, Chirumbolo S. Phytochemicals as Chemical Promoters of the Adaptive Chaos in Health Recovery. A Modelling Investigation. Chem Biodivers. 2025 Apr 9:e202500078. **PUNTEGGIO CITE SCORE 3.4 terzo quartile 49% SU INVITO**
26. Bjørklund G, Tirelli U, Chirumbolo S, Valdenassi L. Effect of SARS-CoV2 S protein on red blood cells parameters. Some comments. Biomed J. 2025 Apr 22:100857. **PUNTEGGIO CITE SCORE 11.6 primo quartile 95%**
27. Valdenassi L, Bjørklund G, Tirelli U, Chirumbolo S. The Environmental Impact of Inappropriate Clinical Laboratory Testing: What's New? J Appl Lab Med. 2025 Apr 23:jfaf050. **PUNTEGGIO CITE SCORE 3.7 secondo quartile 62%**
28. Chirumbolo S, Ricevuti G, Franzini M, Vaiano F, Galoforo CA, Richelmi T, Tirelli U, Valdenassi L. Oxygen-ozone adjunct therapy in aging and senescence-related disorders. State of art. Advances in Pharmacology **PUNTEGGIO CITE SCORE 9.1 primo quartile 85%**
29. Chirumbolo S, Franzini M, Tirelli U. Post-infective myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-COVID as two puzzling faces of the same medal. Recent insights. Int Immunopharmacol. 2025 Mar 7:114365. . **PUNTEGGIO CITE SCORE 8.4 primo quartile 80%**
30. Chirumbolo S, Tirelli U. Some comments on Tecovirimat and mpox. Eur J Intern Med. 2025 Mar 1:S0953-6205(25)00080-9. **PUNTEGGIO CITE SCORE 9.6 primo quartile 87%**
31. Chirumbolo S, Tirelli U. Some comments on the efficiency and simulation of Thailand's Chiang Mai University model for COVID-19 mass vaccination hub. Am J Infect Control. 2025 Feb;53(2):279-280. **PUNTEGGIO CITE SCORE 9.0 primo quartile 93%**
32. Zanet E, Tadorelli M, Tirelli U, Diez-Martin J, Balsalobre P, Re A, Rupolo M, Mazzucato M, Cwynarski K, Gomez MRV, Guillerm G, Serraino D, Ciancia R, Chirumbolo S, Carbone A, Michieli M. Long-Term Clinical Outcomes After Autologous Hematopoietic Stem Cell Transplantation in 49 Individuals Living With HIV (PLWH) and Affected by High-Risk or Relapsed Lymphoma: A European Experience of Continued Relevance for PLWH. J Med Virol. 2025 Jan;97(1):e70165. **PUNTEGGIO CITE SCORE 23.2 primo quartile 96%**
33. Chirumbolo S, Franzini M, Valdenassi L. About the ozone ability in using adaptive chaos to restore a healthy state in the oxygen-ozone adjunct therapy. Int Immunopharmacol. 2024 Dec 30;147:113967. **PUNTEGGIO CITE SCORE 8.4 primo quartile 80%**
34. Franzini M, Vaiano F, Tirelli U, Chirumbolo S, Valdenassi L. SIOOT recommendations for the optimal application of the oxygen-ozone therapy in clinical medicine. Int Immunopharmacol. 2025 Jan 3;145:113751. **PUNTEGGIO CITE SCORE 8.4 primo quartile 80%**
35. Chirumbolo S, Franzini M, Tirelli U, Valdenassi L. The use of ozone in the anti-aging and wellbeing proposals. A proof of concern. Int Immunopharmacol. 2024 Nov 22:113609. doi: 10.1016/j.intimp.2024.113609. **PUNTEGGIO CITE SCORE 8.4 primo quartile 80%**
36. Chirumbolo S, Valdenassi L, Tirelli U, Richelmi T, Franzini M. Successful treatment of aspergillosis in a 63-years old female patient with a SIOOT protocol of oxygen-ozone autohemotherapy: A case report. Int Immunopharmacol. 2024 Nov 5;143(Pt 3):113561. **PUNTEGGIO CITE SCORE 8.4 primo quartile 80%**
37. Chirumbolo S, Valdenassi L, Richelmi T, Tirelli U, Franzini M. Ozone and procaine in knee osteoarthritis. Friend or foe? Int Immunopharmacol. 2024 Nov 2:113507. **PUNTEGGIO CITE SCORE 8.4 primo quartile 80%**
38. Franzini M, Valdenassi L, Tirelli U, Vaiano F, Chirumbolo S. Haemolysis is a concerning bias in some ozone therapy approaches. Int Immunopharmacol. 2024 Nov 4;143(Pt 3):113512. **PUNTEGGIO CITE SCORE 8.4 primo quartile 80%**



39. Valdenassi L, Franzini M, Ricevuti G, Tirelli U, Carlo Galoforo A, Vaiano F, Chirumbolo S. Efficacy of oxygen-ozone therapy against the pro-necrotic action of *Loxosceles rufescens* toxic bite. *Int Immunopharmacol*. 2024 Sep 21;142(Pt B):113112. **PUNTEGGIO CITE SCORE 8.4 primo quartile 80%**
40. Pandolfi S, Chirumbolo S, Franzini M, Tirelli U, Valdenassi L. Oxygen-ozone therapy for myocardial ischemic stroke and cardiovascular disorders. *Med Gas Res*. 2024 Aug 31. doi: 10.4103/mgr.MEDGASRES-D-23-00013. **PUNTEGGIO CITE SCORE 5.1 secondo quartile 74%**
41. Scassellati C, Bonvicini C, Ciani M, Zanardini R, Tomasoni E, Saletti V, Passeggia I, Almici M, Pagnoni I, Galoforo AC, Costa M, D'Onofrio M, Cattaneo A, Geroldi C. Cognitive, Neuropsychological and Biological Effects of Oxygen-Ozone Therapy on Frailty: A Study Protocol for a 5-Week, Randomized, Placebo-Controlled Trial. *J Pers Med*. 2024 Jul 27;14(8):795.
42. Franzini M, Valdenassi L, Vaiano F, Richelmi T, Tirelli U, Chirumbolo S. Criticism on the Incorrect Use of Oxygen-Ozone Therapy in Medicine. *J Pineal Res*. 2024 Sep;76(6):e13005. **PUNTEGGIO CITE SCORE 17.7 primo quartile 95%**
43. Chirumbolo S, Franzini M, Tirelli U, Richelmi T, Vaiano F, Carlo Galoforo A, Valdenassi L. The use of "combined" approaches in ozone therapy. More chaffs than wheat. *Int Immunopharmacol*. 2024 Oct 25;140:112809. **PUNTEGGIO CITE SCORE 8.4 primo quartile 80%**
44. Chirumbolo S, Franzini M, Tirelli U, Pandolfi S, Valdenassi L. Letter to the Editor Regarding "Neuroprotective Effects of Coenzyme Q10 and Ozone Therapy on Experimental Traumatic Spinal Cord Injuries in Rats" *World Neurosurgery*, 2024; 189: 495 **PUNTEGGIO CITE SCORE 3.9 primo quartile 75%**
45. Chirumbolo S, Valdenassi L, Franzini M, Richelmi T, Tirelli U. Comments on the use of ozone therapy in post-acute sequelae of COVID-19 (PASC) patients. *Int Immunopharmacol*. 2024 Oct 25;140:112770. **PUNTEGGIO CITE SCORE 8.4 primo quartile 80%**
46. Chirumbolo S, Valdenassi L, Tirelli U, Franzini M. Ozone therapy may not be suitable as a primary treatment for cancer. *J Control Release*. 2024 Aug;372:713-714. **PUNTEGGIO CITE SCORE 18.5 primo quartile 98%**
47. Cascini F., Franzini M, Andreoli A, Manzotti A., Cadeddu C., Quaranta G., Gentili A. Ricciardi W. Use of oxygen-ozone therapy to improve the effectiveness of antibiotic treatment on infected arthroplasty: protocol for a superiority, openlabel, multicentre, randomised, parallel trial, *BMJ OPEN* 2024, 14e076739 doi 10.1136 2023-076739 **PUNTEGGIO CITE SCORE 4.4 primo quartile 81%**
48. Franzini M, Tirelli U, Valdenassi L, Vaiano F, Galoforo AC, Ricevuti G, Chirumbolo S. Oxygen-ozone therapy in the medical sciences. State of art. *Int Immunopharmacol*. 2024 Jun 22:112489. doi: 10.1016/j.intimp.2024.112489. **PUNTEGGIO CITE SCORE 8.4 primo quartile 84%**
49. Chirumbolo S, Valdenassi L, Pandolfi S, Tirelli U, Franzini M. Medical use of adjunct oxygen ozone-therapy and its impact on the scientific literature to date. *The Lancet Reg Health Americas* 2024 Volume 35 July 2024 Article number 100807, 10.1016/j.lana.2024.100807 **PUNTEGGIO CITE SCORE 8.0 primo quartile 92%**
50. Valdenassi L, Chierchia M, Pandolfi S, Bellardi D, Chirumbolo S, Franzini M. Adjunct treatment with ozone to enhance therapy of knee osteoarthritis: preliminary results. *Clin Rheumatol*.



2024 Jun;43(6):2093-2101. doi: 10.1007/s10067-024-06972- **PUNTEGGIO CITE SCORE 6,9 primo quartile 78%**

51. Chirumbolo S, Franzini M, Tirelli U. Does PI-ME/CFS recall post-COVID (PASC) syndrome? *Virus Res.* 2024 Jul;345:199393. doi: 10.1016/j.virusres.2024.199393. **PUNTEGGIO CITE SCORE 9.5 primo quartile 85%**
52. Chirumbolo S, Pandolfi S, Valdenassi L, Chierchia M, Franzini M. Complications During Ozone Therapy as a Result of Malpractice and Lack of Guidelines. *Clin Neuroradiol.* 2024 Apr 23. doi: 10.1007/s00062-024-01412-4. **PUNTEGGIO CITE SCORE 5.0 secondo quartile 69%**
53. Chirumbolo S, Valdenassi L, Tirelli U, Pandolfi S, Franzini M. The use of the medical ozone in the immune challenge of multidrug resistant (MDR) bacteria and the role of mitochondria. *Microbes Infect.* 2024 Jan-Feb;26(1-2):105242. **PUNTEGGIO CITE SCORE 12.6 primo quartile 91%**
54. Chirumbolo S, Berretta M, Tirelli U. Trust, trustworthiness and acceptability of a machine learning adoption in data-driven clinical decision support system. Some comments. *Int J Med Inform.* 2024 Apr;184:105374. **PUNTEGGIO CITE SCORE 8.9 primo quartile 82%**
55. Chirumbolo S, Tirelli U. On coming back, the scaring COVID-19 concern. Addressing indoor microclimates with innovative and straightforward solutions to prevent SARS-CoV2 spreading. *J Med Virol.* 2024 Feb;96(2):e29490. **PUNTEGGIO CITE SCORE 23.2 primo quartile 96%**
56. Chirumbolo S, Franzini M, Pandolfi S, Valdenassi L. Ozonated water in painful periodontitis and photo biomodulation (PBM) therapy: some comments. *Lasers Med Sci.* 2024 Jan 17;39(1):32. **PUNTEGGIO CITE SCORE 4.5 primo quartile 80%**
57. Chirumbolo S, Franzini M, Pandolfi S, Tirelli U, Valdenassi L. Commentary: Ozone therapy as a novel complementary therapeutic approach in refractory idiopathic granulomatous mastitis. *Front Med (Lausanne).* 2023 Dec 11;10:1272059. **PUNTEGGIO CITE SCORE 18.3 primo quartile 97%**
58. Chirumbolo S, Valdenassi L, Tirelli U, Ricevuti G, Pandolfi S, Vaiano F, Galoforo A, Loprete F, Simonetti V, Chierchia M, Bellardi D, Richelmi T, Franzini M. The Oxygen-Ozone Adjunct Medical Treatment According to the Protocols from the Italian Scientific Society of Oxygen-Ozone Therapy: How Ozone Applications in the Blood Can Influence Clinical Therapy Success via the Modulation of Cell Biology and Immunity. *Biology (Basel).* 2023 Dec 11;12(12):1512. **PUNTEGGIO CITE SCORE 5.7 primo quartile 85%**
59. Tirelli U, Valdenassi L, Franzini M, Pandolfi S, Fisichella R, Chirumbolo S. Oxygen-ozone autohemotherapy in breast cancer patients suffering from fatigue and musculoskeletal pain upon aromatase inhibitors treatment: a case-series study. *Eur Rev Med Pharmacol Sci.* 2023 Dec;27(23):11643-11652. **PUNTEGGIO CITE SCORE 5.3 secondo quartile 64%**
60. Chirumbolo S, Tirelli U, Franzini M, Pandolfi S, Ricevuti G, Vaiano F, Valdenassi L. Ozone in the adjunct medical treatment. The round personality of a molecule with hormetic properties. *Hum Exp Toxicol.* 2023 Jan-Dec;42:9603271231218926. **PUNTEGGIO CITE SCORE 5.7 secondo quartile 63%**
61. Franzini M, Valdenassi L, Pandolfi S, Tirelli U, Ricevuti G, Chirumbolo S. The Role of Ozone as an Nrf2-Keap1-ARE Activator in the Anti-Microbial Activity and Immunity Modulation of Infected Wounds. *Antioxidants (Basel).* 2023 Nov 8;12(11):1985 **PUNTEGGIO CITE SCORE 10.6 primo quartile 92%**
62. Chirumbolo S, Valdenassi L, Franzini M. Ozone adjunct treatment in facing multidrug-resistant bacteria? *Clin Case Rep.* 2023 Oct 18;11(10):e8087.



63. Chirumbolo S, Franzini M, Tirelli U, Valdenassi L. Photodynamic therapy at 810nm, associated with ozonated water, may concurrently prevent periodontitis exacerbation and restore dental health. *Photodiagnosis Photodyn Ther.* 2023 Dec;44:103842. **PUNTEGGIO CITE SCORE 5.8 primo quartile 86%**
64. Chirumbolo S, Pandolfi S, Franzini M, Valdenassi L. Cytokine profiles in COVID-19 patients undergoing adjunct ozone therapy: some comments. *Inflammopharmacology.* 2023 Dec;31(6):3363-3365. **PUNTEGGIO CITE SCORE 8.0 primo quartile 86%**
65. Chirumbolo S, Franzini M, Tirelli U. Artificial intelligence (AI) in the medical consultation: Friend or foe? *Int J Med Inform.* 2023 Nov;179:105227. **PUNTEGGIO CITE SCORE 8.9 primo quartile 82%**
66. Chirumbolo S, Franzini M, Valdenassi L, Pandolfi S. Ozone in the ischemia/reperfusion (I/R) injury. Lessons for ozone therapy in myocardial ischemia. *Biomed Pharmacother.* 2023 Nov;167:115482. **PUNTEGGIO CITE SCORE 11.9 primo quartile 91%**
67. Tirelli U, Chirumbolo S. In Italy Banning Smoking Has Not Worked. How Crucial Are New Nicotine-Delivery Devices in Reducing Tobacco-Related Health Risk? *Nicotine Tob Res.* 2023 Nov 22;25(12):1909-1911. **PUNTEGGIO CITE SCORE 8.1 primo quartile 90%**
68. Franzini M, Valdenassi L, Chirumbolo S. The immune mito-hormetic landscape in the oxygen-ozone therapy. Towards a novel medical approach. *Int Immunopharmacol.* 2023 Aug;121:110598. **PUNTEGGIO CITE SCORE 8.4 primo quartile 84%**
69. Tirelli U, Cirrito C, Pavanello M, Chirumbolo S, Franzini M, Berretta M. Lung cancer and COVID-19: problems and perspectives. *Eur Rev Med Pharmacol Sci.* 2023 Jun;27(12):5918-5926. **PUNTEGGIO CITE SCORE 5.3 secondo quartile 64%**
70. Chirumbolo S, Tirelli U. Post-COVID or long-COVID? That is the question. *Pol Arch Intern Med.* 2023 May 23;133(5):16506. **PUNTEGGIO CITE SCORE 4.5 secondo quartile 60%**
71. Varesi A, Campagnoli LIM, Barbieri A, Rossi L, Ricevuti G, Esposito C, Chirumbolo S, Marchesi N, Pascale A. RNA binding proteins in senescence: A potential common linker for age-related diseases? *Ageing Res Rev.* 2023 Jul;88:101958. **PUNTEGGIO CITE SCORE 19.8 primo quartile 98%**
72. Varesi A, Campagnoli LIM, Chirumbolo S, Candiano B, Carrara A, Ricevuti G, Esposito C, Pascale A. The brain-gut-microbiota interplay in depression: A key to design innovative therapeutic approaches. *Pharmacol Res.* 2023 Jun;192:106799. **PUNTEGGIO CITE SCORE 18.7 primo quartile 97%**
73. Chierchia M, Chirumbolo S, Valdenassi L, Franzini M. Ozone-treated poly-ε-caprolactone scaffolds for bone regeneration. *Chem Biol Interact.* 2023 Aug 25;381:110509. **PUNTEGGIO CITE SCORE 7.7 primo quartile 84%**
74. Chirumbolo S, Gibellini D, Berto L, Cirrito C, Vella A, Bjørklund G, Sbarbati A, Bernardi P, Tirelli U. TiO₂-Ag-NP adhesive photocatalytic films able to disinfect living indoor spaces with a straightforward approach. *Sci Rep.* 2023 Mar 14;13(1):4200. **PUNTEGGIO CITE SCORE 7.5 primo quartile 92%**
75. Varesi A, Campagnoli LIM, Carrara A, Pola I, Floris E, Ricevuti G, Chirumbolo S, Pascale A. Non-Enzymatic Antioxidants against Alzheimer's Disease: Prevention, Diagnosis and Therapy. *Antioxidants (Basel).* 2023 Jan 12;12(1):180. **PUNTEGGIO CITE SCORE 10.6 primo quartile 92%**
76. Chirumbolo S, Valdenassi L, Simonetti V, Pandolfi S. Comments on "To clarify the safety profile of paracetamol for home-care patients with COVID-19: a real-world cohort study, with



nested case-control analysis, in primary care". Intern Emerg Med. 2023 Apr;18(3):955.

PUNTEGGIO CITE SCORE 7.2 primo quartile 92%

77. Franzini M, Valdenassi L, Pandolfi S, Ricevuti G, Tirelli U, Vaiano F, Chirumbolo S. Comments on the optimal use of medical ozone in clinics versus the Ozone High Dose Therapy (OHT) approach. Transl Med Commun. 2022;7(1):26.
78. Tirelli U, Franzini M, Valdenassi L, Pandolfi S, Taibi R, Chirumbolo S. Fibromyalgia treated with oxygen-ozone auto-haemotherapy (O2-O3-AHT): a case study on 200 patients with a modified 10-PI-NRS evaluation. Eur Rev Med Pharmacol Sci. 2022 Nov;26(21):7974-7979. **PUNTEGGIO CITE SCORE 5.3 secondo quartile 64%**
79. Varesi A, Campagnoli LIM, Fahmideh F, Pierella E, Romeo M, Ricevuti G, Nicoletta M, Chirumbolo S, Pascale A. The Interplay between Gut Microbiota and Parkinson's Disease: Implications on Diagnosis and Treatment. Int J Mol Sci. 2022 Oct 14;23(20):12289. **PUNTEGGIO CITE SCORE 8.1 primo quartile 90%**
80. Franzini M, Valdenassi L, Pandolfi S, Tirelli U, Ricevuti G, Simonetti V, Berretta M, Vaiano F, Chirumbolo S. The biological activity of medical ozone in the hormetic range and the role of full expertise professionals. Front Public Health. 2022 Sep 16;10:979076. **PUNTEGGIO CITE SCORE 4.8 secondo quartile 70%**
81. Chirumbolo S, Varesi A, Franzini M, Valdenassi L, Pandolfi S, Tirelli U, Esposito C, Ricevuti G. The Mito-Hormetic Mechanisms of Ozone in the Clearance of SARS-CoV2 and in the COVID-19 Therapy. Biomedicines. 2022 Sep 12;10(9):2258. **PUNTEGGIO CITE SCORE 5.2 secondo quartile 74%**
82. Valdenassi L, Rossi E, Corsetti MT, Sarli R, Bellardi D, Chirumbolo S, Simonetti V, Pandolfi S, Franzini M. Sjögren syndrome successfully treated with oxygen-ozone auto-hemotherapy (O2-O3-AHT). a case report. Eur Rev Med Pharmacol Sci. 2022 Aug;26(16):5911-5917. **PUNTEGGIO CITE SCORE 5.3 secondo quartile 64%**
83. Varesi A, Chirumbolo S, Campagnoli LIM, Pierella E, Piccini GB, Carrara A, Ricevuti G, Scassellati C, Bonvicini C, Pascale A. The Role of Antioxidants in the Interplay between Oxidative Stress and Senescence. Antioxidants (Basel). 2022 Jun 22;11(7):1224. **PUNTEGGIO CITE SCORE 10.6 primo quartile 92%**
84. Varesi A, Carrara A, Pires VG, Floris V, Pierella E, Savioli G, Prasad S, Esposito C, Ricevuti G, Chirumbolo S, Pascale A. Blood-Based Biomarkers for Alzheimer's Disease Diagnosis and Progression: An Overview. Cells. 2022 Apr 17;11(8):1367. . **PUNTEGGIO CITE SCORE 9.9 primo quartile 84%**
85. Cenci A, Macchia I, La Sorsa V, Sbarigia C, Di Donna V, Pietraforte D, Mechanisms of Action of Ozone Therapy in Emerging Viral Diseases: Immunomodulatory Effects and Therapeutic Advantages With Relevance to SARS-CoV-2. Frontiers. 2022 Apr 21. 10.3389/fmicb.2022.871645
86. Chirumbolo S, Simonetti V, Valdenassi L, Pandolfi S, Vaiano F, Franzini M. Editorial - A practical assessment to prevent serious complications in the use of a gaseous mixture of oxygen-ozone injected by needle-mediated infiltration. Eur Rev Med Pharmacol Sci. 2022 Apr;26(7):2224-2226. **PUNTEGGIO CITE SCORE 5.3 secondo quartile 64%**
87. Pandolfi S, Valdenassi L, Bjørklund G, Chirumbolo S, Lysiuk R, Lenchyk L, Doşa MD, Fazio S. COVID-19 Medical and Pharmacological Management in the European Countries Compared to Italy: An Overview. Int J Environ Res Public Health. 2022 Apr 2;19(7):4262. **PUNTEGGIO CITE SCORE 7.3 primo quartile 86%**



88. Chirumbolo S, Pandolfi S, Valdenassi L. Seasonality of COVID-19 deaths. Did social restrictions and vaccination actually impact the official reported dynamic of COVID-19 pandemic in Italy? *Environ Res.* 2022 Sep;212(Pt B):113229. **PUNTEGGIO CITE SCORE 12.6 primo quartile 96%**
89. Chirumbolo S, Tirelli U. Integrating medical knowledge to improve science with a novel, straightforward attitude: the bio-integrative medicine. *Eur Rev Med Pharmacol Sci.* 2022 Mar;26(5):1433-1434. **PUNTEGGIO CITE SCORE 5.3 secondo quartile 64%**
90. Varesi A, Pierella E, Romeo M, Piccini GB, Alfano C, Bjørklund G, Oppong A, Ricevuti G, Esposito C, Chirumbolo S, Pascale A. The Potential Role of Gut Microbiota in Alzheimer's Disease: From Diagnosis to Treatment. *Nutrients.* 2022 Feb 5;14(3):668. **PUNTEGGIO CITE SCORE 9.2 primo quartile 89%**
91. Chirumbolo S, Pandolfi S. Escaping from COVID-19 emergency accounting on previously infected subjects? *J Med Virol.* 2022 Jun;94(6):2352-2353. **PUNTEGGIO CITE SCORE 23.2 primo quartile 96%**
92. Chirumbolo S, Valdenassi L, Franzini M, Pandolfi S, Ricevuti G, Tirelli U. Male vs. Female Differences in Responding to Oxygen-Ozone Autohemotherapy (O₂-O₃-AHT) in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). *J Clin Med.* 2021 Dec 29;11(1):173. **PUNTEGGIO CITE SCORE 5.7 primo quartile 87%**
93. Tirelli U, Franzini M, Valdenassi L, Pandolfi S, Berretta M, Ricevuti G, Chirumbolo S. Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Greatly Improved Fatigue Symptoms When Treated with Oxygen-Ozone Autohemotherapy. *J Clin Med.* 2021 Dec 22;11(1):29. **PUNTEGGIO CITE SCORE 23.2 primo quartile 96%**
94. Pandolfi S, Chirumbolo S, Ricevuti G, Valdenassi L, Bjørklund G, Lysiuk R, Doşa MD, Lenchyk L, Fazio S. Home pharmacological therapy in early COVID-19 to prevent hospitalization and reduce mortality: Time for a suitable proposal. *Basic Clin Pharmacol Toxicol.* 2022 Feb;130(2):225-239. **PUNTEGGIO CITE SCORE 5.6 secondo quartile 60%**
95. Varesi A, Chirumbolo S, Ricevuti G. Oxygen-ozone treatment and COVID-19: antioxidants targeting endothelia lead the scenery. *Intern Emerg Med.* 2022 Mar;17(2):593-596. **PUNTEGGIO CITE SCORE 7.2 primo quartile 92%**
96. Tirelli U, Franzini M, Valdenassi L, Pisconti S, Taibi R, Torrisi C, Pandolfi S, Chirumbolo S. Fatigue in post-acute sequelae of SARS-CoV2 (PASC) treated with oxygen-ozone autohemotherapy - preliminary results on 100 patients. *Eur Rev Med Pharmacol Sci.* 2021 Sep;25(18):5871-5875. **PUNTEGGIO CITE SCORE 5.3 secondo quartile 64%**
97. Pandolfi S, Chirumbolo S. Home therapy of COVID-19 at the earliest may greatly prevent hospitalization. *Basic Clin Pharmacol Toxicol.* 2021 Dec;129(6):395-396. **PUNTEGGIO CITE SCORE 5.6 secondo quartile 60%**
98. Pandolfi S, Chirumbolo S. On reaching herd immunity during the COVID-19 pandemic and further issues. *J Med Virol.* 2022 Jan;94(1):24-25. **PUNTEGGIO CITE SCORE 23.2 primo quartile 96%**
99. Tirelli U, Taibi R, Chirumbolo S. Post COVID syndrome: a new challenge for medicine. *Eur Rev Med Pharmacol Sci.* 2021 Jun;25(12):4422-4425. **PUNTEGGIO CITE SCORE 5.3 secondo quartile 64%**
100. Pandolfi S, Simonetti V, Ricevuti G, Chirumbolo S. Paracetamol in the home treatment of early COVID-19 symptoms: A possible foe rather than a friend for elderly patients? *J Med Virol.* 2021 Oct;93(10):5704-5706. **PUNTEGGIO CITE SCORE 23.2 primo quartile 96%**



101. Chirumbolo S, Valdenassi L, Simonetti V, Bertossi D, Ricevuti G, Franzini M, Pandolfi S. Insights on the mechanisms of action of ozone in the medical therapy against COVID-19. *Int Immunopharmacol*. 2021 Jul;96:107777. **PUNTEGGIO CITE SCORE 8.4 primo quartile 84%**
102. Tirelli U, Chirumbolo S. COVID-19 and cancer: A deadly pairing. *Int J Cancer*. 2021 Sep 1;149(5):1199-1200. **PUNTEGGIO CITE SCORE 13.4 primo quartile 90%**
103. Chirumbolo S, Simonetti V, Franzini M, Valdenassi L, Bertossi D, Pandolfi S. Estimating coronavirus disease 2019 (COVID-19)-caused deaths in hospitals and healthcare units: Do hospital-acquired infections play a role? Comments with a proposal. *Infect Control Hosp Epidemiol*. 2022 Jun;43(6):810-811. **PUNTEGGIO CITE SCORE 6.4 secondo quartile 73%**
104. Chirumbolo S, Franzini M, Simonetti V, Valdenassi L, Ricevuti G, Bertossi D, Pandolfi S. Oxygen-ozone autohemotherapy against COVID-19 needs to fit highly experienced, customized, and standardized protocols to succeed. *J Med Virol*. 2021 May;93(5):2580-2582. **PUNTEGGIO CITE SCORE 23.2 primo quartile 96%**
105. Chirumbolo S, Pandolfi S, Valdenassi L, Bertossi D, Franzini M. The need for a correct oxygen-ozone autohemotherapy (O₃-AHT) in patients with mild to moderate COVID-19 pneumonia. *Intern Emerg Med*. 2021 Apr;16(3):793-794. **PUNTEGGIO CITE SCORE 7.2 primo quartile 92%**
106. Franzini M, Valdenassi L, Ricevuti G, Chirumbolo S, Depfenhart M, Bertossi D, Tirelli U. Oxygen-ozone (O₂-O₃) immunocutaneous therapy for patients with COVID-19. Preliminary evidence reported. *Int Immunopharmacol*. 2020 Nov;88:106879. **PUNTEGGIO CITE SCORE 8.4 primo quartile 84%**
107. Chirumbolo S, Franzini M, Pandolfi S, Valdenassi L. Ozone Therapy in the Huge Concern of Multidrug Resistant (MDR) bacteria. The Worldwide Perspective. *Occupational Medicine and Health Affairs* 2023; 11.478
108. Chirumbolo S, Valdenassi L, Franzini M. COVID-19 home therapy: it has never been a matter of freedom of cure *J Pharmacy Pharmacol Res* 2023 7(3):175-176
109. Scassellati C, Ciani M, Galoforo AC, Zanardini R, Bonvicini C, Geroldi C. Corrigendum to "Molecular mechanisms in cognitive frailty: Potential therapeutic targets for oxygen-ozone treatment" [*Mech. Ageing Dev.* 186 (2020) 111210]. *Mech Ageing Dev.* 2022 Oct;207:111729. doi: 10.1016/j.mad.2022.111729. Epub 2022 Sep 2. Erratum for: *Mech Ageing Dev.* 2020 Mar;186:111210. PMID: 36058726. **PUNTEGGIO CITE SCORE 8.4 primo quartile 84%**
110. Wu J, Tan CS, Yu H, Wang Y, Tian Y, Shao W, Zhang Y, Zhang K, Shao H, Ni G, Shen J, Galoforo AC, Wu Q, Ming D. Recovery of Four COVID-19 Patients via Ozonated Autohemotherapy. *Innovation (Camb)*. 2020 Nov 25;1(3):100060. doi: 10.1016/j.xinn.2020.100060. Epub 2020 Nov 4. PMID: 33169118; PMCID: PMC7609231. **PUNTEGGIO CITE SCORE 38.3 primo quartile 98%**
111. Gavazza A, Marchegiani A, Rossi G, Franzini M, Spaterna A, Mangiaterra S, Cerquetella M. Ozone Therapy as a Possible Option in COVID-19 Management. *Front Public Health*. 2020 Aug 25;8:417. doi: 10.3389/fpubh.2020.00417. PMID: 32984235; PMCID: PMC7477102. **PUNTEGGIO CITE SCORE 4.8 secondo quartile 70%**
112. Scassellati C, Galoforo AC, Bonvicini C, Esposito C, Ricevuti G. Ozone: a natural bioactive molecule with antioxidant property as potential new strategy in aging and in neurodegenerative disorders. *Ageing Res Rev.* 2020 Nov;63:101138. doi:



10.1016/j.arr.2020.101138. Epub 2020 Aug 15. PMID: 32810649; PMCID: PMC7428719.

PUNTEGGIO CITE SCORE 19.8 primo quartile 98%

- 113.** Valdenassi L, Franzini M, Ricevuti G, Rinaldi L, Galoforo AC, Tirelli U. Potential mechanisms by which the oxygen-ozone (O₂-O₃) therapy could contribute to the treatment against the coronavirus COVID-19. *Eur Rev Med Pharmacol Sci.* 2020 Apr;24(8):4059-4061. doi: 10.26355/eurrev_202004_20976. PMID: 32374009. **PUNTEGGIO CITE SCORE 5.3 secondo quartile 64%**
- 114.** Scassellati C, Ciani M, Galoforo AC, Zanardini R, Bonvicini C, Geroldi C. Molecular mechanisms in cognitive frailty: potential therapeutic targets for oxygen-ozone treatment. *Mech Ageing Dev.* 2020 Mar;186:111210. doi: 10.1016/j.mad.2020.111210. Epub 2020 Jan 23. Erratum in: *Mech Ageing Dev.* 2022 Oct;207:111729. PMID: 31982474. **PUNTEGGIO CITE SCORE 8.4 primo quartile 84%**
- 115.** Simonetti V, Quagliariello V, Franzini M, Iaffaioli RV, Maurea N, Valdenassi L. Ozone Exerts Cytoprotective and Anti-Inflammatory Effects in Cardiomyocytes and Skin Fibroblasts after Incubation with Doxorubicin. *Evid Based Complement Alternat Med.* 2019 Nov 18;2019:2169103. doi: 10.1155/2019/2169103. PMID: 31827546; PMCID: PMC6885772.
- 116.** Tirelli U, Cirrito C, Pavanello M, Piasentin C, Lleshi A, Taibi R. Ozone therapy in 65 patients with fibromyalgia: an effective therapy. *Eur Rev Med Pharmacol Sci.* 2019 Feb;23(4):1786-1788. doi: 10.26355/eurrev_201902_17141. PMID: 30840304. **PUNTEGGIO CITE SCORE 5.3 secondo quartile 64%**
- 117.** Tirelli U, Cirrito C, Pavanello M, Del Pup L, Lleshi A, Berretta M. Oxygen-ozone therapy as support and palliative therapy in 50 cancer patients with fatigue - A short report. *Eur Rev Med Pharmacol Sci.* 2018 Nov;22(22):8030-8033. doi: 10.26355/eurrev_201811_16432. PMID: 30536352. **PUNTEGGIO CITE SCORE 5.3 secondo quartile 64%**
- 118.** Simonetti V, Quagliariello V, Giustetto P, Franzini M, Iaffaioli RV. Corrigendum to "Association of Ozone with 5-Fluorouracil and Cisplatin in Regulation of Human Colon Cancer Cell Viability: In Vitro Anti-Inflammatory Properties of Ozone in Colon Cancer Cells Exposed to Lipopolysaccharides". *Evid Based Complement Alternat Med.* 2018 Apr 30;2018:3297906. doi: 10.1155/2018/3297906. Erratum for: *Evid Based Complement Alternat Med.* 2017;2017:7414083. PMID: 29855623; PMCID: PMC5952567.
- 119.** Simonetti V, Quagliariello V, Giustetto P, Franzini M, Iaffaioli RV. Association of Ozone with 5-Fluorouracil and Cisplatin in Regulation of Human Colon Cancer Cell Viability: In Vitro Anti-Inflammatory Properties of Ozone in Colon Cancer Cells Exposed to Lipopolysaccharides. *Evid Based Complement Alternat Med.* 2017;2017:7414083. doi: 10.1155/2017/7414083. Epub 2017 Jul 4. Erratum in: *Evid Based Complement Alternat Med.* 2018 Apr 30;2018:3297906. PMID: 29721026; PMCID: PMC5868048.
- 120.** Molinari F, Rimini D, Liboni W, Acharya UR, Franzini M, Pandolfi S, Ricevuti G, Vaiano F, Valdenassi L, Simonetti V. Cerebrovascular pattern improved by ozone autohemotherapy: an entropy-based study on multiple sclerosis patients. *Med Biol Eng Comput.* 2017 Aug;55(8):1163-1175. doi: 10.1007/s11517-016-1580-z. Epub 2016 Oct 12. PMID: 27734309. **PUNTEGGIO CITE SCORE 5.3 secondo quartile 64%**
- 121.** Molinari F, Simonetti V, Franzini M, Pandolfi S, Vaiano F, Valdenassi L, Liboni W. Ozone autohemotherapy induces long-term cerebral metabolic changes in multiple sclerosis patients. *Int J Immunopathol Pharmacol.* 2014 Jul-Sep;27(3):379-89. **PUNTEGGIO CITE SCORE 4.0 terzo quartile 44%**



122. Franzini M., Bignamini A., Valdenassi L., Agostini G., Richelmi P., Berte F. Subcutaneous oxygen ozone therapy in indurative hypodermatitis and in localized lipofystrophies: a clinical study of efficacy and tollerability. *Acta Toxicologia et Therapeutica* 14.272-1993
123. Franzini M., Valdenassi L., Richelmi P. Valutazione dell'attività dell'ossigeno ozono sulle teleangectasie cutanee di superficie *Acta Toxicologica Ther.* Vol. XVII n. 2-3, 1996
124. Franzini M., Biondi G., Zini M.F., Bramanti E., Benedetti E., Agostini G., Vergamini P. Benedetti E. – Reactivity of nucleic acids with ozone: an FT-IR microspectroscopy study – *Applied Spectroscopy* Vol 51 n. 10,35 1997 **PUNTEGGIO CITE SCORE 6.6 primo quartile 79%**
125. Franzini M., Valdenassi L., Richelmi P., Berte F., - L'ossigeno ozono nella medicina fisica e riabilitativa – *Trattato di Medicina fisica e riabilitazione Utet* Vol 2 pag 1355-1360
126. Paoloni M, Di Sante L., Cacchio A., Marotta S., Razzano M., Franzini M. Intramuscular Oxygen-Ozone Therapy in the treatment of acute back pain with lumbar disc Hernation. *Spine* vol 34 Number 13, pp 1337-1344 2009. **PUNTEGGIO CITE SCORE 6.6 primo quartile 79%**
127. Lintas G., Liboni W., Simonetti V., Franzini M., Valdenassi L., Vaiano F., Pandolfi S., Molinari F. – Long Term cerebrovascular reactivity mediated by ozone autohemotherapy: a nirs study – *GNB2012*, june 26-29 2012
128. Lintas G., Liboni W., Simonetti V., Franzini M. Molinari G., - Time and time-frequency analysis of near-infrared signals for the assessment of ozone autohemotherapy long-term effects in multiple sclerosis – *Conf. Proc. IEEE Eng. Med. Biol. Soc.* 2013:6171-4 doi: 10.1109/EMBC 2013 6610962 Pubme PMID 24111149
129. Bonforte G., Bellasi A. Riva H., Ferradini M., Arrighi E., Groppi G., Mingretti C., M. Franzini – Ozone Therapy: un potenziale ulteriore approccio alle infezioni delle basse vie urinarie: a case series report – *G. Ital Nefrol.* 2013; 30 (4) ISSN 1724-5590 – 2013 PUBMED PMID 24403204
130. M. Franzini, L. Valdenassi – First Evaluations of oxygen ozone therapy in antibiotic resistant infections – *Ozone Therapy* 2016 vol. 1:5838
131. P. Wentworth, J. E. McDunn, A. D. Wentworth, C. Takeuchi, J. Nieva, T. Jones, C. Bautista, J. M. Ruedi, A. Guitierrez, K. D. Janda, B. M. Bablor, Al Eschenmoser, R. A. Lerner – Evidence for Antibody Catalized Ozone Formation in Bacterial Killing and Inflammation – *SCIENCE* Vol. 298 13.12.2002

(1) I punteggi non assegnati dipendono da vari motivi: a) la rivista non è più esistente o è cambiata o non è più citata per i lavori datati; b) il lavoro è in lingua italiana; c) la rivista non è impattata; d) la rivista non ha un citescore; e) il testo è un libro o una relazione a Congresso

VALUTAZIONE PRODOTTI DELLA RICERCA

80 su 128 pubblicazioni sono di qualità eccellente (Q1) corrispondenti a circa il 62.50%. I lavori di elevata qualità (Q1+Q2) rappresentano l'83.59% del totale delle pubblicazioni (107/128)
Il 99.35% delle pubblicazioni eseguite negli ultimi anni sono di qualità Q1 e Q2